Please use this identifier to cite or link to this item:
|Title:||Targeted alpha therapy of glioblastoma multiforme: clinical experience with 213Bi- and 225Ac-Substance P|
|Authors:||KROLICKI LESZEK; BRUCHERTSEIFER FRANK; KUNIKOWSKA JOLANTA; KOZIARA H; KROLICKI B; JAKUCINSKI M; PAWLAK DARIUSZ; APOSTOLIDIS CHRISTOS; ROLA R; MERLO A.; MORGENSTERN ALFRED|
|Publisher:||European Commission - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, has a very poor prognosis with a median overall survival of 14.6 months despite of aggressive therapy. Targeted alpha therapy (TAT) with the short range, high LET alpha emitters 213Bi and 225Ac offers the potential for selective irradiation of tumors and minimizing damage to adjacent regions of the brain. The low-molecular weight peptide carrier substance P is targeting NK 1 receptors, which are consistently over-expressed on GBM cells. We report our clinical experience with 213Bi-DOTA-Substance P (213Bi-SP) and 225Ac-DOTAGA-Substance P (225Ac-SP) in patients with recurrent GBM.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.